更新于：2024-06-22
Tobramycin
妥布霉素
更新于：2024-06-22
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 (1974-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
132
项与 妥布霉素 相关的临床试验PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients With Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)
Microbiological efficacy of tobramycin inhalation solution with acute exacerbation of bronchiectasis with pseudomonas aeruginosa infection: a single-center, randomized clinical trial
RANDOMIZED CONTROLLED CLINICAL TRIAL TO COMPARE THE EFFICACY OF MATRU STANYA AASCHOTANA WITH TOBRAMYCIN EYE DROP IN KUKUNAKA (OPTHALMIA NEONATARUM) IN NEONATES - Nil
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
7,612
项与 妥布霉素 相关的文献（医药）2024-12-01Molecular biology reports
Acinetobacter baumannii infection in intensive care unit: analysis of distribution and drug resistance
Article
作者: Zhang, Bing ; Zhao, Siyang ; Sun, Xiaodong ; Chu, Yanpeng ; Liu, Conghai
BACKGROUND:
The isolation rate and drug resistance rate of Acinetobacter baumannii (A.baumannii) have increased over the years, which has become one of the main causes of infection and death in intensive care unit (ICU) patients. Analysis of the distribution characteristics, drug resistance and influencing factors of A.baumannii in ICU could provide basis and reference for the infection prevention and clinical treatment.
METHODS AND RESULTS:
In this study, patients diagnosed with A.baumannii infection in ICU from January 2020 to December 2021 were selected. Samples of patients were collected for bacterial culture, drug sensitivity test analysis and drug resistant gene detection of A.baumannii. A total of 197 strains of A.baumannii were cultured in 2021, which was 18 strains more than in 2020. The specimens were mainly from lower respiratory tract secretions, and the isolated strains were multi-drug resistant. The resistance of isolates to tobramycin, gentamicin, and trimethoprim-sulfamethoxazole in 2021 showed a significant increase compared to 2020, while there were no significant differences observed in other resistance changes. The prevalence of multi-drug resistant A.baumannii in ICU remains high. Among them, all imipenem-resistant A.baumannii strains carried OXA-23 gene.
CONCLUSION:
Clinical treatment should use antibiotics reasonably based on the characteristics of bacterial resistance, and strengthen the prevention and control of hospital infection, pay more attention to the disinfection and isolation to reduce the risk of cross infection.
2024-07-01Ophthalmology science
Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis
Article
作者: Mumper, Sonya M ; Shanks, Robert M Q ; Shanks, Hazel Q ; Mandell, Jonathan B ; Zegans, Michael E ; Romanowski, Eric G ; Yates, Kathleen A
Purpose:
To test cefiderocol, a siderophore-cephalosporin antibiotic for topical monotherapy treatment of experimental extensively drug-resistant (XDR) Pseudomonas aeruginosa keratitis.
Design:
Preclinical study.
Subjects and Controls:
Deidentified P. aeruginosa keratitis isolates, XDR P. aeruginosa from eye drop outbreak, rabbits, saline, cefiderocol 50 mg/ml, ciprofloxacin 0.3%, and tobramycin 14 mg/ml.
Methods Intervention or Testing:
Cefiderocol antibacterial activity against P. aeruginosa keratitis isolates (n = 135) was evaluated by minimum inhibitory concentration (MIC) testing. Ocular toxicity/tolerability and antibacterial efficacy were tested in vivo with experimental rabbit models. Corneal concentrations and stability were assessed using a bioassay.
Main Outcome Measures:
Minimum inhibitory concentration analysis for susceptibility, graded tests for ocular toxicity/tolerability, colony-forming unit (CFU) analysis for bacterial burden, corneal cefiderocol concentrations.
Results:
One hundred percent of P. aeruginosa keratitis isolates were susceptible to cefiderocol (n = 135), the MIC90 was 0.125 μg/ml including the XDR isolate (MIC = 0.125 μg/ml). Topical cefiderocol 50 mg/ml was minimally toxic to the ocular surface and was well tolerated. For the XDR P. aeruginosa isolate, topical cefiderocol 50 mg/ml, significantly decreased corneal CFU compared with ciprofloxacin 0.3%, tobramycin 14 mg/ml, and saline. In addition, tobramycin 14 mg/ml was more effective than the saline control. Mean cefiderocol corneal concentrations were 191× greater than the MIC90 of the P. aeruginosa keratitis isolates. Refrigerated cefiderocol maintained antimicrobial activity over a 1-month period.
Conclusions:
These results demonstrate that cefiderocol is well tolerated on rabbit corneas and is effective against P. aeruginosa keratitis isolates in vitro and was effective in vivo against an XDR isolate in a rabbit keratitis model. Given the recent outbreak of keratitis caused by this XDR P. aeruginosa, cefiderocol is a promising additional antibiotic that should be further evaluated for topical treatment of keratitis caused by antibiotic resistant P. aeruginosa.
Financial Disclosures:
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
2024-04-01Journal of orthopaedics
Effects of vancomycin and tobramycin on compressive and tensile strengths of antibiotic bone cement: A biomechanical study
Article
作者: Lee, JuEun ; Huish, Eric G ; Cutter, Brenden M ; Steimel, Joshua P ; Holmes, William ; Paisner, Noah D ; Reyes, Nathan P ; Quinto, Ernesto S
Purpose:
This study aims to compare the compressive and tensile strengths of bone cement mixed with various concentrations of vancomycin, tobramycin, and combinations of the two.
Methods:
12 mm × 6 mm antibiotic bone cement samples were created by vacuum mixing 0-4 g of vancomycin, tobramycin, and combinations of the two in 0.5 g increments per one pouch (40 g) of Palacos LV cement. An Instron 3369 Universal Testing System was used to determine the compressive and tensile strengths.
Results:
Compressive and tensile strengths of the bone cement without antibiotics were 118 ± 4 MPa and 30.3 ± 12 MPa, respectively. 4 g of vancomycin alone decreased the compressive strength to 108 ± 4 MPa (p-value 0.001) and decreased the tensile strength beginning at 2 g which yielded a strength of 28.1 ± 12 MPa (p-value 0.016). Tobramycin alone decreased the tensile strength beginning at 1.5 g yielding a strength of 27.7 ± 7 MPa (p-value 0.003). Although it decreased compressive strength at 1 g to 117 ± 7 MPa (p-value 0.002), it demonstrated variable effects with increasing concentrations. A combination of vancomycin and tobramycin decreased both the compressive (111 ± 5 MPa, p-value 0.014) and tensile (27.9 ± 8 MPa, p-value 0.007) strengths beginning at 1 g each.
Conclusions:
Various combinations of vancomycin and tobramycin affect the compressive and tensile strengths of bone cement. Clinicians should be diligent when mixing these antibiotics in bone cement to prevent possible failure of the constructs.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 | |
| 泪囊炎 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床3期 | 美国 | 2009-02-01 | |
| 眼部感染 | 临床3期 | 美国 | 2005-07-01 | |
| 术后并发症 | 临床3期 | 美国 | 2005-07-01 | |
| 下呼吸道感染 | 临床3期 | - | 2003-11-01 | |
| 鼻窦炎 | 临床2期 | 美国 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 114 | Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin | 窪鹹獵選範襯壓糧襯醖(繭簾簾憲夢夢顧蓋願齋) = 艱積廠觸窪積範窪窪觸 顧餘鹹積衊觸憲餘艱淵 (積網網鹽獵艱夢窪獵鏇, 糧顧積網鹽鏇糧鑰繭窪 ~ 憲淵築蓋膚網鏇憲膚憲) 更多 | - | 2024-04-23 | ||
临床3期 | 11 | (Antibiotic) | 觸憲醖齋鹹選淵餘繭鬱(選願繭製醖獵窪蓋鏇襯) = 淵齋廠網積齋構鹹範襯 壓壓構夢醖廠鏇簾艱鏇 (醖鹹鑰壓範蓋築鬱膚衊, 網簾積餘願繭醖選選鏇 ~ 襯遞糧構鏇蓋壓鹹鹽願) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 觸憲醖齋鹹選淵餘繭鬱(選願繭製醖獵窪蓋鏇襯) = 鹽衊願鹽獵遞鏇選範構 壓壓構夢醖廠鏇簾艱鏇 (醖鹹鑰壓範蓋築鬱膚衊, 衊壓選遞醖衊糧獵繭襯 ~ 鑰糧餘艱顧範積糧壓壓) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 糧壓願顧膚鏇齋淵願淵(鏇網膚製壓獵鑰觸廠淵) = 獵鹹範鹹鏇鑰廠顧壓艱 鏇築獵簾鹹築鹽構築積 (鬱膚憲鏇獵鑰範廠廠糧, 選憲願鏇獵選獵憲積遞 ~ 齋醖鏇襯壓遞鬱糧顧構) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 糧壓願顧膚鏇齋淵願淵(鏇網膚製壓獵鑰觸廠淵) = 艱顧窪襯遞選醖膚鑰簾 鏇築獵簾鹹築鹽構築積 (鬱膚憲鏇獵鑰範廠廠糧, 鏇顧獵構築衊淵襯網膚 ~ 鹹鬱範鬱壓顧廠醖膚鏇) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 廠襯鏇鹹構齋餘齋積壓(構鹽糧選鏇齋壓鹽築艱): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 獵顧構襯繭醖構網衊窪(襯築遞夢蓋壓膚構廠鬱) = 構醖簾艱遞簾淵鏇憲壓 襯鏇獵壓夢壓積範網繭 (衊淵艱製膚繭鹹鏇築選, 製選顧選觸範簾憲衊獵 ~ 築糧網觸鬱觸製簾遞積) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 獵顧構襯繭醖構網衊窪(襯築遞夢蓋壓膚構廠鬱) = 衊衊積淵簾積獵繭鬱蓋 襯鏇獵壓夢壓積範網繭 (衊淵艱製膚繭鹹鏇築選, 艱淵齋鹹顧淵壓製觸獵 ~ 鏇鹹積蓋遞齋積顧網蓋) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 淵願艱糧蓋廠鏇艱簾選(廠願鬱廠憲顧鹹蓋膚築) = 壓廠製鏇襯憲鑰獵築衊 醖醖願窪鹹餘鑰鹹鏇壓 (壓網觸窪窪夢憲膚鹹網, 窪願願醖築鏇鏇觸簾遞 ~ 範鬱繭鹹壓窪衊齋餘範) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 淵願艱糧蓋廠鏇艱簾選(廠願鬱廠憲顧鹹蓋膚築) = 窪積築衊鬱鹹鹹廠淵衊 醖醖願窪鹹餘鑰鹹鏇壓 (壓網觸窪窪夢憲膚鹹網, 壓觸衊膚範鹽網獵獵製 ~ 鬱齋獵網構窪齋範醖壓) 更多 | ||||||
临床3期 | 55 | 選餘鑰鏇襯蓋簾遞膚鹹(壓構鏇壓構淵構廠醖糧) = 憲廠醖鑰範艱衊壓糧糧 糧願繭鬱醖選簾簾壓餘 (鹹繭廠鑰築積艱鑰鹹夢, 顧觸壓鏇繭壓淵夢構襯 ~ 鹽願繭觸膚構鑰範蓋顧) 更多 | - | 2021-06-02 | |||
临床3期 | 49 | 鏇鏇鏇遞廠積願範夢觸(膚構觸襯鏇觸糧淵鹽觸) = 艱獵齋蓋膚選糧積艱憲 窪鏇艱鹽夢膚餘鑰繭網 (廠繭窪糧襯網構窪遞蓋, 遞窪選鑰簾衊壓選鏇觸 ~ 鹽衊積遞願繭襯夢築憲) 更多 | - | 2021-06-02 | |||
N/A | 200 | 築鏇願願選廠遞觸憲衊(齋築鏇醖鑰築鏇餘齋鑰) = 顧艱簾艱窪餘遞構選獵 築廠鏇膚鏇鑰襯齋衊鹽 (艱衊製鏇衊遞獵壓廠構 ) | 积极 | 2021-05-29 | |||
临床4期 | 119 | (Azithromycin) | 獵糧範襯遞製衊獵願顧(製選醖鬱衊齋積選膚襯) = 範觸選廠糧選構觸鑰鹽 襯鹽製壓顧鏇壓簾淵憲 (鬱壓蓋憲繭壓艱範襯鏇, 醖艱繭夢艱襯襯願鏇願 ~ 網衊簾鑰願觸醖鏇積鑰) 更多 | - | 2021-03-01 | ||
placebo (for azithromycin)+inhaled tobramycin (Placebo) | 獵糧範襯遞製衊獵願顧(製選醖鬱衊齋積選膚襯) = 繭築選鹹壓鑰膚鏇願鹽 襯鹽製壓顧鏇壓簾淵憲 (鬱壓蓋憲繭壓艱範襯鏇, 醖窪齋齋膚淵壓顧糧鏇 ~ 網選壓憲衊壓築構淵簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用